Trials / Completed
CompletedNCT00189254
A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ
A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1487-IMIQ Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 72 (planned)
- Sponsor
- MEDA Pharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to obtain recurrence rates and long-term safety data for patients who had been treating actinic keratoses on the face and scalp with 5 % Imiquimod Cream in a previous study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod | No defined treatments were given during this study. |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2005-11-01
- Completion
- 2005-11-01
- First posted
- 2005-09-19
- Last updated
- 2022-02-07
Source: ClinicalTrials.gov record NCT00189254. Inclusion in this directory is not an endorsement.